title: Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme.
abstract: Five patients with the early-onset form of Alzheimer disease (AD) received GM1 ganglioside by continuous injection into the frontal horns of the lateral ventricles for a period of 12 months. The optimal GM1 dose varied between 20 and 30 mg/24 h. The patients were trained twice a week for 4-5 h with an individually designed cognitive programme, which included the use of a word processor. Neurological, neuropsychological, psychiatric and neurochemical examinations were performed a week before surgery and on days 30, 90, 180, 270 and 365 after surgery. The cerebrospinal fluid levels of the monoamine metabolites homovanillic acid and 5-hydroxyindoleacetic acid and the neuropeptide somatostatin increased. The regional cerebral blood flow showed a tendency to increase. The progression of deterioration was stopped, and motor performance and neuropsychological assessments improved. The patients became more active and felt safer in relation to other people and performing various activities. They had improved reading comprehension and a better feeling for language. They were able to write reports and short letters on a word processor. When interviewed at the end of the study, all 5 patients stated that they felt better, and their relatives reported that they had regained integrity and their joie de vivre.
authors.affiliation: Department of Clinical Neuroscience, Göteburg University, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Svennerholm
authors.forename: Görel
authors.initials: G
authors.lastname: Bråne
authors.forename: Ingvar
authors.initials: I
authors.lastname: Karlsson
authors.forename: Annika
authors.initials: A
authors.lastname: Lekman
authors.forename: Ingalill
authors.initials: I
authors.lastname: Ramström
authors.forename: Carsten
authors.initials: C
authors.lastname: Wikkelsö
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology / Q000534:rehabilitation; D002560:Cerebrovascular Circulation; D005260:Female; D005677:G(M1) Ganglioside / Q000008:administration & dosage / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D013004:Somatostatin / Q000134:cerebrospinal fluid; D016896:Treatment Outcome
chemical_list: D005677:G(M1) Ganglioside; D013004:Somatostatin; D006897:Hydroxyindoleacetic Acid; D006719:Homovanillic Acid